论文部分内容阅读
目的探讨尿激酶对高龄急性脑梗死患者的静脉溶栓效果及其安全性。方法选择本院2012年4月~2014年4月收治的年龄≥70岁的急性脑梗死患者40例,均符合溶栓条件,其中家属同意溶栓治疗有20例,即溶栓治疗组;家属不同意溶栓治疗有20例,即非溶栓治疗组,设为对照组,比较2组治疗前后NIHSS评分、mRS评分及预后情况。结果 2组治疗后近期各时间段NIHSS评分与治疗前相比均有明显降低(P<0.05),但溶栓治疗组降低程度显著优于非溶栓治疗组(P<0.05);2组患者在治疗后mRS评分远期疗效比较存在明显差异(P<0.05);2组患者治疗后出血并发症发生率、病死率比较无显著性差异(P>0.05)。结论尿激酶对高龄急性梗死患者的静脉溶栓效果肯定,并发症发生较少。
Objective To investigate the efficacy and safety of urokinase in elderly patients with acute cerebral infarction. Methods Forty patients with acute cerebral infarction aged ≥70 years admitted from April 2012 to April 2014 in our hospital were enrolled in this study. All of them were eligible for thrombolytic therapy, of whom 20 were considered thrombolytic therapy, Do not agree with thrombolytic therapy in 20 cases, the non-thrombolytic treatment group, as the control group, the NIHSS score, mRS score and prognosis of the two groups before and after treatment were compared. Results The NIHSS scores of the two groups after treatment were significantly lower than those before treatment (P <0.05), but the degree of reduction in the thrombolytic therapy group was significantly better than that of the non-thrombolytic therapy group (P <0.05) There was significant difference in the long-term effect of mRS score after treatment between the two groups (P <0.05). There was no significant difference in the complication rate and mortality between the two groups after treatment (P> 0.05). Conclusions Urokinase has certain effect on intravenous thrombolysis in elderly patients with acute infarction, with less complications.